Valeant considering sale of eye-surgery assets — Carl Zeiss interest rumored

Bloomberg reports Valeant Pharmaceuticals is considering selling its Bausch & Lomb surgical products to Carl Zeiss Meditec.

Advertisement

Here’s what you should know:

1. Analysts believe Bausch & Lomb is worth $2 billion.

2. Anonymous sources told Bloomberg talks are ongoing with an agreement “still weeks away.”

3. Valeant could consider other bidders.

4. Valeant has $28.9 billion in debt. CEO Joe Papa is working to stabilize the company after it suffered from government pricing probes coupled with poor sales.

More articles on improving health:
ASCA Healthcare Asset Network to create online shopping portal: 4 features
10 states where the most people delay necessary medical care
20 latest notes on hourly, annual wages for ASC nurses, tech & administrative staff

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Register to Attend Webinar

Is ambulatory care healthcare’s big margin engine? 4 leaders weigh in

Wednesday, July 29
1:00 PM - 2:00 PM CDT

Presenters: Joe Ganley, athenahealthJeffrey Flynn, CASC, Gramercy Surgery CenterBryan Tsao, Access Center, Loma Linda University HealthJason Zepeda, Northridge Hospital Medical Center, CommonSpirit HealthGreg DeConciliis, PA-C, CASC, Boston Out­Patient Surgical Suites

Advertisement

Next Up in ASC News

Advertisement

Comments are closed.